LIXTE BIOTECHNOLOGY HOLDINGS(NASDAQ:LIXT) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to LIXT. LIXT was compared to 568 industry peers in the Biotechnology industry. While LIXT seems to be doing ok healthwise, there are quite some concerns on its profitability. LIXT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

LIXT had negative earnings in the past year.

In the past year LIXT has reported a negative cash flow from operations.

In the past 5 years LIXT always reported negative net income.

In the past 5 years LIXT always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of LIXT (-313.04%) is worse than 94.54% of its industry peers.

LIXT has a Return On Equity of -433.50%. This is in the lower half of the industry: LIXT underperforms 77.99% of its industry peers.

		Industry Rank	Sector Rank
ROA	-313.04%
ROE	-433.5%
ROIC	N/A

ROA(3y)-181.53%

ROA(5y)-147.83%

ROE(3y)-227.63%

ROE(5y)-177.69%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LIXT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, LIXT has about the same amount of shares outstanding.

The number of shares outstanding for LIXT has been increased compared to 5 years ago.

LIXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -66.49, we must say that LIXT is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -66.49, LIXT is not doing good in the industry: 95.07% of the companies in the same industry are doing better.

There is no outstanding debt for LIXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-66.49

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.60 indicates that LIXT has no problem at all paying its short term obligations.

LIXT has a Current ratio (3.60) which is comparable to the rest of the industry.

LIXT has a Quick Ratio of 3.60. This indicates that LIXT is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 3.60, LIXT perfoms like the industry average, outperforming 44.89% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.6
Quick Ratio	3.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LIXT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.43%, which is quite impressive.

EPS 1Y (TTM)42.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%40.07%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LIXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for LIXT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (4/24/2025, 2:25:08 PM)

1.2997

0 (-0.02%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-24 2025-03-24/bmo

Earnings (Next)05-07 2025-05-07

Inst Owners11.28%

Inst Owner Change22.78%

Ins Owners8.1%

Ins Owner Change0%

Market Cap3.48M

Analysts0

Price TargetN/A

Short Float %1.94%

Short Ratio0.56

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	4.21
P/tB	4.21
EV/EBITDA	N/A

EPS(TTM)-1.59

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.18

FCFYN/A

OCF(TTM)-1.18

OCFYN/A

SpS0

BVpS0.31

TBVpS0.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-313.04%
ROE	-433.5%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-181.53%

ROA(5y)-147.83%

ROE(3y)-227.63%

ROE(5y)-177.69%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.6
Quick Ratio	3.6
Altman-Z	-66.49

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%40.07%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y29.81%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y26.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y26.29%

OCF growth 3YN/A

OCF growth 5YN/A

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens